Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Income: 2020-2025

Historic Operating Income for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $6.7 million.

  • Xeris Biopharma Holdings' Operating Income rose 152.21% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 121.70%. This contributed to the annual value of -$33.6 million for FY2024, which is 23.55% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Operating Income of $6.7 million as of Q3 2025, which was up 50.18% from $4.5 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Operating Income's 5-year high stood at $6.7 million during Q3 2025, with a 5-year trough of -$48.3 million in Q4 2021.
  • Moreover, its 3-year median value for Operating Income was -$8.2 million (2024), whereas its average is -$6.3 million.
  • Its Operating Income has fluctuated over the past 5 years, first tumbled by 162.43% in 2024, then spiked by 154.75% in 2025.
  • Xeris Biopharma Holdings' Operating Income (Quarterly) stood at -$48.3 million in 2021, then soared by 68.57% to -$15.2 million in 2022, then soared by 35.13% to -$9.8 million in 2023, then skyrocketed by 117.06% to $1.7 million in 2024, then soared by 152.21% to $6.7 million in 2025.
  • Its Operating Income stands at $6.7 million for Q3 2025, versus $4.5 million for Q2 2025 and -$3.1 million for Q1 2025.